newsfilter
← Latest News
GlobeNewswire·

Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business Update

Company Focuses on Development of Neuromuscular Blocking Agents Phase II Randomized Trial for BX1000 Initiated, Positive Interim Results Announced; Completion of Study Enrollment Expected Q1 2023, Top Line Results